Palobiofarma has received FDA approval to initiate a Phase I clinical trial with the novel adenosine A2b antagonist PBF-1129 in lung cancer patients. The trial will be conducted at Ohio State University Comprehensive Cancer Center, Ohio, USA.
News
FDA grants Palobiofarma approval to start second anti-cancer study in USA
2
Related News
2
Palobiofarma initiates clinical development of it´s novel dual PDE10/A2a antagonist in solid tumors
Palobiofarma has received FDA approval to initiate a Phase I clinical trial with the novel...
No Comments
2
Palobiofarma advances it´s broad clinical pipeline
Palobiofarma has received FDA approval to initiate a Phase I clinical trial with the novel...
No Comments
2
Palobiofarma completed the dose escalation part of the Phase I study with PBF-999 in cancer patients
Palobiofarma has received FDA approval to initiate a Phase I clinical trial with the novel...
3 Comments
0
Palobiofarma has started the clinical development of PBF-1650
Palobiofarma has received FDA approval to initiate a Phase I clinical trial with the novel...
No Comments
2
Palobiofarma achieves “first patient first visit” in two key Phase II studies
Palobiofarma has received FDA approval to initiate a Phase I clinical trial with the novel...
No Comments